High prevalence of peribronchial focal lesions of airway invasive aspergillosis in hematological cancer patients with prolonged neutropenia
Adult
Invasive Pulmonary Aspergillosis
Male
Neutropenia
Galactose
Bronchial Diseases
Middle Aged
3. Good health
Mannans
Young Adult
03 medical and health sciences
0302 clinical medicine
Hematologic Neoplasms
Bronchoscopy
Prevalence
Humans
Female
Tomography, X-Ray Computed
Biomarkers
Aged
Retrospective Studies
DOI:
10.1259/bjr.20190693
Publication Date:
2020-05-28T09:57:36Z
AUTHORS (8)
ABSTRACT
Objective:
The aim of this study is to characterize chest CT findings of neutropenic patients with proven/probable invasive pulmonary aspergillosis (IPA).
Methods:
Hematological cancer patients admitted to our institution (2007–2017) were retrospectively enrolled if the diagnostic criteria of proven/probable IPA during the neutropenia were met (EORTC/MSG). Galactomannan (GM) was routinely measured in serum and chest CT-scan was routinely performed in case of recurrent/persistent fever. Bronchoscopy was performed in case of chest CT-scan abnormalities. Chest CT-scan and GM dosage were analyzed at the time of IPA suspicion. Chest lesions were classified using a clinical report form by two expert radiologists.
Results:
35 patients were identified. Peribronchial focal lesions were observed in 29 IPA (82.9%) by the first radiologist and in 31 (88.5%) by the second (k = 0.768). 12 weeks mortality was 20%.
Conclusion:
Peribronchial focal lesions are a common finding in early-IPA whatever the GM value during neutropenia and our findings reinforce the efficiency of a preemptive approach.
Advances in knowledge;
Peribronchial focal lesions, which are classically described in airway invasive aspergillosis, are a common finding in early-IPA in hematological cancer patients with prolonged neutropenia regardless of the GM value, and such peribronchial lesions should reinforce the possibility of IPA.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (22)
CITATIONS (3)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....